Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMDI7SA)

Drug Name
MEDI3506 Drug Info
Synonyms Tozorakimab
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMDI7SA

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-33 (IL33) TT5MD4P IL33_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-33 (IL33) DTT IL33 5.162 4.096 3.053 3.954
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Chronic obstructive pulmonary disease
ICD Disease Classification CA22
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-33 (IL33) DTT IL33 1.19E-01 -0.03 -0.03
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.